Homology Medicines Inc (FIXX) Receives $29.50 Consensus Target Price from Brokerages

Homology Medicines Inc (NASDAQ:FIXX) has been given an average rating of “Buy” by the eight brokerages that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $29.50.

Several analysts recently issued reports on FIXX shares. Zacks Investment Research downgraded Homology Medicines from a “buy” rating to a “hold” rating in a research note on Monday, October 15th. ValuEngine downgraded Homology Medicines from a “buy” rating to a “hold” rating in a research note on Friday, December 7th. Finally, Canaccord Genuity started coverage on Homology Medicines in a research note on Monday, January 7th. They issued a “buy” rating and a $37.00 price target for the company.

Shares of FIXX stock traded up $0.46 during trading on Monday, reaching $21.89. 63,500 shares of the company’s stock were exchanged, compared to its average volume of 117,143. Homology Medicines has a twelve month low of $15.07 and a twelve month high of $26.50.

Homology Medicines (NASDAQ:FIXX) last released its quarterly earnings results on Tuesday, November 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.03). The company had revenue of $0.95 million during the quarter. Equities analysts forecast that Homology Medicines will post -1.49 EPS for the current year.

In other news, Director Kush Parmar sold 15,575 shares of the company’s stock in a transaction on Monday, December 10th. The stock was sold at an average price of $26.01, for a total transaction of $405,105.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Ventures Iv L.P. 5Am sold 29,682 shares of the company’s stock in a transaction on Friday, November 23rd. The shares were sold at an average price of $20.04, for a total value of $594,827.28. The disclosure for this sale can be found here. Insiders sold a total of 571,157 shares of company stock valued at $11,623,113 over the last 90 days.

Several large investors have recently added to or reduced their stakes in the company. TD Asset Management Inc. lifted its position in shares of Homology Medicines by 3.9% during the 4th quarter. TD Asset Management Inc. now owns 24,068 shares of the company’s stock valued at $538,000 after acquiring an additional 900 shares during the period. Vanguard Group Inc lifted its position in shares of Homology Medicines by 0.7% during the 3rd quarter. Vanguard Group Inc now owns 473,945 shares of the company’s stock valued at $10,834,000 after acquiring an additional 3,504 shares during the period. Vanguard Group Inc. lifted its position in shares of Homology Medicines by 0.7% during the 3rd quarter. Vanguard Group Inc. now owns 473,945 shares of the company’s stock valued at $10,834,000 after acquiring an additional 3,504 shares during the period. Wells Fargo & Company MN lifted its position in shares of Homology Medicines by 246.7% during the 3rd quarter. Wells Fargo & Company MN now owns 6,167 shares of the company’s stock valued at $141,000 after acquiring an additional 4,388 shares during the period. Finally, Essex Investment Management Co. LLC bought a new stake in shares of Homology Medicines during the 4th quarter valued at $169,000. Hedge funds and other institutional investors own 53.17% of the company’s stock.

Homology Medicines Company Profile

Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Featured Story: Why is the conference call important?

Analyst Recommendations for Homology Medicines (NASDAQ:FIXX)

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit